XFOR - X4 shares jump as FDA accepts priority review of pediatric WHIM drug
2023-10-31 10:35:43 ET
More on X4 Pharmaceuticals
- X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market
- X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Earnings Call Transcript
- X4 submits New Drug Application to FDA for WHIM syndrome drug
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
- Historical earnings data for X4 Pharmaceuticals
For further details see:
X4 shares jump as FDA accepts priority review of pediatric WHIM drug